Efficacy and safety of Syk/VEGFR-2 Dual-target Kinase Inhibitor (OT202) in Dry Eye: A Randomized, Vehicle-controlled, Phase 2 Trial

Journal:

Ophthalmology

Published:

2025-11-04

DOI:

10.1016/j.ophtha.2025.10.023

Affiliations:

11

Authors:

11

Go to article

Institutions	Authors	Share
Affiliated Eye Hospital, WMU, China	2.000000	0.18
The Second Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.09
Ningbo Aier Eye Hospital, China	1.000000	0.09
Affiliated Hospital of Yunnan University, China	1.000000	0.09
Tianjin Medical University Eye Hospital (TMUEH), TMU, China	1.000000	0.09
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.09
Renmin Hospital of Wuhan University/Hubei General Hospital, China	1.000000	0.09
The Third Xiangya Hospital, CSU, China	1.000000	0.09
Wuhan Union Hospital, HUST, China	1.000000	0.09
Tianjin Medical University (TMU), China	1.000000	0.09

Interested in Ophthalmology and Optometry?